Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioCardia ( (BCDA) ) has issued an announcement.
On March 3, 2026, BioCardia reported late-breaking echocardiography data from its Phase III CardiAMP HF trial in ischemic heart failure with reduced ejection fraction, presented at the Technology and Heart Failure Therapeutics conference. The autologous CardiAMP cell therapy showed evidence of reduced pathological left ventricular remodeling over time compared with control patients, an outcome considered prognostic for better long-term results in this population.
Echocardiography analyses by a blinded Yale core lab found trends toward smaller ventricular volumes overall and statistically significant, clinically meaningful reductions in both end-diastolic and end-systolic volumes for a prespecified subgroup with elevated heart-stress biomarkers. Investigators highlighted that these structural benefits aligned with previously reported reductions in major adverse cardiovascular events and improvements in quality of life, reinforcing CardiAMP’s potential value in a large heart-failure market with limited effective treatment options.
The most recent analyst rating on (BCDA) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
The score is primarily constrained by very weak financial performance (no meaningful revenue, ongoing losses, and sustained cash burn), which elevates funding risk. Technicals also remain bearish with the stock below major moving averages, despite oversold signals. Positive clinical/regulatory updates and stated runway into 2026 provide some support, but do not outweigh the current financial and trend headwinds.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., based in Sunnyvale, Calif., is a developer of cellular and cell-derived therapeutics targeting cardiovascular and pulmonary diseases. Its pipeline includes CardiAMP autologous and CardiALLO allogeneic cell therapies, supported by proprietary catheter-based delivery and vascular navigation platforms aimed at treating heart failure and related conditions.
The company’s CardiAMP Cell Therapy for heart failure holds FDA Breakthrough designation and is being advanced through multiple cardiac clinical-stage programs. BioCardia also partners with other biotherapeutic developers to provide its specialized delivery technologies, positioning the firm as both a therapeutic and platform technology player in the cardiovascular space.
Average Trading Volume: 78,689
Technical Sentiment Signal: Sell
Current Market Cap: $14.33M
For an in-depth examination of BCDA stock, go to TipRanks’ Overview page.